Reckitt Benckiser pays Merck & Co £100 million for product rights
This article was originally published in Scrip
Executive Summary
Reckitt Benckiser is to pay £100 million to Merck & Co's MSD business to buy back sales and marketing rights to three opiate products, Suboxone, Subutex and Temgesic, in certain European and rest of world markets.